Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DDB1 | Q16531 | 4/20 | 0.52 |
| ▸ | CRBN | Q96SW2 | 4/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.41 |
| ▸ | NPC1 | O15118 | 2/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.41 |
| ▸ | RAB9A | P51151 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | QDPR | P09417 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 2/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | CASP3 | P42574 | 1/20 | 0.40 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.40 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.40 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | CNR1 | P21554 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29225363 | 0.87 | DDB1 (0.51) | DDB1CRBNALDH1A1SMN1; SMN2NPC1 | |
| SCHEMBL23120656 | 0.83 | NAMPT (0.52) | DDB1CRBNCNR1 | |
| SCHEMBL29264345 | 0.83 | DDB1 (0.47) | DDB1CRBNALDH1A1SMN1; SMN2NPC1 | |
| SCHEMBL22324772 | 0.79 | ALDH1A1 (0.56) | ALDH1A1SMN1; SMN2NPC1ALOX15RAB9A | |
| SCHEMBL26621442 | 0.77 | DDB1 (0.59) | DDB1CRBNALDH1A1SMN1; SMN2MEN1 | |
| SCHEMBL29007105 | 0.77 | CRBN (0.59) | DDB1CRBNALDH1A1SMN1; SMN2MEN1 | |
| SCHEMBL27762102 | 0.76 | ALDH1A1 (0.50) | ALDH1A1SMN1; SMN2NPC1ALOX15RAB9A | |
| SCHEMBL23121268 | 0.76 | ALDH1A1 (0.35) | DDB1CRBNALDH1A1SMN1; SMN2NPC1 | |
| SCHEMBL22325027 | 0.75 | F10 (0.41) | ALDH1A1SMN1; SMN2NPC1ALOX15RAB9A | |
| SCHEMBL25333581 | 0.75 | DDB1 (0.56) | DDB1CRBNALDH1A1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220387602-A1 | BIFUNCTIONAL DEGRADERS AND THEIR METHODS OF USE | NOVARTIS AG (CH) | 2022-12-08 | — | — | US | disclosed |
| EP-4031247-A1 | BIFUNCTIONAL DEGRADERS AND THEIR METHODS OF USE | Novartis AG (CH) | 2022-07-27 | — | — | EP | disclosed |
| WO-2021053495-A1 | BIFUNCTIONAL DEGRADERS AND THEIR METHODS OF USE | NOVARTIS AG (CH) | 2021-03-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220387602-A1 | BIFUNCTIONAL DEGRADERS AND THEIR METHODS OF USE | JMJD7, MDM2, IDE | DDB1 612/4885CRBN 241/4885ALDH1A1 2189/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.